本文選題：慢性乙肝　切入點(diǎn)：恩替卡韋　出處：《基層醫(yī)學(xué)論壇》2016年35期

【摘要】：目的研究恩替卡韋與干擾素聯(lián)合治療慢性乙肝對(duì)患者血清纖維化指標(biāo)的影響。方法將我院收治的400例慢性乙肝患者隨機(jī)分為對(duì)照組200例,使用恩替卡韋治療;治療組200例,采用恩替卡韋與干擾素聯(lián)合治療。觀察2組患者治療前后血清纖維化指標(biāo)與肝功能指標(biāo)變化。結(jié)果治療后,2組患者肝功能指標(biāo)、血清纖維化指標(biāo)均降低,但對(duì)照組患者ALT、TBi L水平及LN、Ⅳ-C、HA、PCⅢ水平下降程度均低于治療組,差異有統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論采用恩替卡韋與干擾素聯(lián)合治療慢性乙肝,可增強(qiáng)抗病毒效果,調(diào)節(jié)肝功能、血清纖維化指標(biāo)水平,減緩肝硬化發(fā)展進(jìn)程。
[Abstract]:Objective to study the effect of entecavir combined with interferon on serum fibrosis in patients with chronic hepatitis B. methods 400 patients with chronic hepatitis B in our hospital were randomly divided into control group (n = 200) and treatment group (n = 200). The changes of serum fibrosis index and liver function index before and after treatment were observed. However, the levels of alt TBi L and LN, 鈪，

本文編號(hào)：1659359